Related Experiment Video
Updated: Oct 4, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Multi-Omics Analysis of the Therapeutic Value of MAL2 Based on Data Mining in Human Cancers
Jing Yuan1, Xiaoyan Jiang1, Hua Lan1
1Department of Gynecology and Obstetrics, Third Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Recent studies have reported that T-cell differentiation protein 2 (MAL2) is an important regulator in cancers. Here, we downloaded data from multiple databases to analyze MAL2 expression and function in pan-cancers, especially in ovarian cancer (OC). Gene Expression Profiling Interactive Analysis (GEPIA) databases was used to examine MAL2 expression in 13 types of cancer. Kaplan-Meier plotter database was used to analyze the overall survival rate of MAL2 in pan-cancers. The Catalog of Somatic Mutations in Cancer (COSMIC), cBioPortal, and UCSC databases were used to examine MAL2 mutation in human cancers. Metascape, STRING, and GeneMANIA websites were used to explore MAL2 function in OC. Furthermore, ggplot2 package and ROC package were performed to analyze hub gene expression and undertake receiver operating characteristic (ROC) analysis. Drug sensitivity of MAL2 in OC was examined by the GSCALite database. In order to verify the results from databases above, real-time quantitative polymerase chain reaction (qRT-PCR) and western blotting were conducted to detect the expression of MAL2 in OC cells. CRISPR/Cas9 system was used to knockout the MAL2 gene in the OC cell lines HO8910 and OVCAR3, using specific guide RNA targeting the exons of MAL2. Then, we performed proliferation, colony formation, migration, and invasion assays to investigate the impact of MAL2 in OC cell lines in vivo and in vitro. Epithelial-mesenchymal transition (EMT)-associated biomarkers were significantly altered in vitro via western blotting and qRT-PCR. Taken together, we observed that MAL2 was remarkably dysregulated in multiple cancers and was related to patient overall survival (OS), mutation, and drug sensitivity. Furthermore, experimental results showed that MAL2 deletion negatively regulated the proliferation, migration, invasion, and EMT of OC, indicating that MAL2 is a novel oncogene that can activate EMT, significantly promote both the proliferation and migration of OC in vitro and in vivo, and provide new clues for treatment strategies.
Insights
T-cell differentiation protein 2 (MAL2) is a novel oncogene in ovarian cancer (OC). Its dysregulation impacts patient survival and drug sensitivity, and MAL2 deletion inhibits OC proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- T-cell differentiation protein 2 (MAL2) has emerged as a significant regulator in various cancers.
- Understanding MAL2's role in pan-cancers, particularly ovarian cancer (OC), is crucial for developing targeted therapies.
Purpose of the Study:
- To comprehensively analyze MAL2 expression, mutation status, and its functional impact on ovarian cancer.
- To investigate MAL2's role in cancer progression, survival, and drug sensitivity across multiple cancer types.
Main Methods:
- Utilized public databases (GEPIA, Kaplan-Meier plotter, COSMIC, cBioPortal, UCSC, GSCALite) for expression, survival, mutation, and drug sensitivity analysis.
- Employed in vitro and in vivo assays, including qRT-PCR, western blotting, CRISPR/Cas9 gene knockout, proliferation, migration, invasion, and EMT marker analysis in OC cell lines.
Main Results:
- MAL2 expression is dysregulated in multiple cancers and correlates with patient overall survival and drug sensitivity.
- MAL2 knockout significantly inhibited proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in OC cell lines.
- MAL2 acts as an oncogene, promoting OC proliferation, migration, and EMT.
Conclusions:
- MAL2 is a novel oncogene in ovarian cancer that promotes proliferation, migration, invasion, and EMT.
- MAL2 dysregulation is linked to patient outcomes and drug sensitivity in pan-cancers.
- Targeting MAL2 may offer new therapeutic strategies for ovarian cancer treatment.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019